F Ayala de la Peña, K Kanasaki, M Kanasaki… - Journal of Biological …, 2011 - ASBMB Activation of oncogenes or inactivation of tumor suppressors in urothelium is considered critical for development of urothelial cancer. Here we report cloning of the urothelium-specific promoter uroplakin-II (UPK II) and generation of transgenic mice in which expression of SV40 large ... Related articles - All 3 versions
N Hayakawa, E Kikuchi, S Mikami… - Japanese Journal of …, 2011 - FPCR Results The multivariate analysis determined that the secondary carcinoma in situ and the absence of bacillus Calmette–Guérin therapy were the independent unfavorable risk factors for tumor recurrence. The 5-year recurrence-free survival rates on primary, concurrent and ... Related articles - All 3 versions
P Nuhn, PJ Bastian, G Novara… - Urologia …, 2011 - content.karger.com ... 3. Utz DC, Hanash KA, Farrow GM: The plight of the patient with carcinoma in situ of the bladder. ... 9. Solsona E, Iborra I, Ricos JV, Dumont R, Casanova JL, Calabuig C: Upper urinary tract involvement in patients with bladdercarcinoma in situ (Tis): its impact on management. ... Related articles - All 2 versions
A Lopez-Beltran, RE Jimenez, R Montironi… - Human Pathology, 2011 - Elsevier We present the clinicopathologic and immunonohistochemical features of 25 cases of flat urothelial carcinoma in situ with glandular differentiation. Previously, cases on this category have been reported as in situ adenocarcinoma (a term not currently preferred). Fourteen of 25 cases ... Related articles - All 3 versions
WL Ooi, M Stockler… - European urology, 2011 - ncbi.nlm.nih.gov Re: Willem Oosterlinck, Ziya Kirkali, Richard Sylvester, et al. Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guérin and with Bacillus Calmette-Guérin Alone in Patients with Carcinoma in Situ of the Urinary Bladder: Results of an EORTC Genito-Urinary ... Related articles - All 2 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
